Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.

Authors:
Feola S; Hamdan F; Russo S; Chiaro J; Fusciello M and 10 more

Journal:
J Immunother Cancer

Publication Year: 2024

DOI:
10.1136/jitc-2023-008342

PMCID:
PMC10928783

PMID:
38458776

View on PubMed View on PMC View Publisher
Journal Information

Journal Title: J Immunother Cancer

Detailed journal information not available.

Publication Details

Subject Category: Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests: VC is a co-founder and shareholder at VALO Therapeutics. SP is a co-founder, an employee, and a shareholder at VALO Therapeutics. VS is currently employed by AstraZeneca. The other authors have no conflicts of interest."

Evidence found in paper:

"Funding: This work was supported by the European Research Council under the European Union's Horizon 2020 Framework program (H2020)/ERC-CoG-2015 Grant Agreement No. 681219, the Helsinki Institute of Life Science (HiLIFE) (797011004), the Jane and Aatos Erkko Foundation (decision 19072019), the Cancer Society of Finland (Syöpäjärjestöt) (4706116) and the Sigrid Juséliuksen Säätiö (8090)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025